SearcharxivSearch

arXiv subjects

Fleur Conway

Publications and source records attributed to Fleur Conway.

2 recordsLinked to original sources

Vancomycert: A Certified Neuro-Symbolic Drug Delivery System (Case Study)

Neural network controllers for autonomous decision-making are well-established in cyber-physical systems, yet their deployment in safety-critical healthcare settings remains largely unverified. This paper presents a methodology and case study for the formal verification of a neural network controller for antibiotic dosing, motivated by the challenge of systems that must be simultaneously adaptive and provably safe across unbounded time horizons. We construct a simplified yet clinically-interpretable model that tracks drug concentration, body temperature, and white blood cell count. Vancomycin is selected as a representative antibiotic, widely prescribed for severe infections yet carrying a narrow therapeutic window, where supratherapeutic concentrations risk nephrotoxicity and subtherapeutic dosing risks treatment failure. A supervised neural network controller is trained on synthetic clinician-style dosing data. We establish formal verification of input-output safety properties, specifically verifying a property of a neural network that implies an infinite-horizon proof that automated dosing never exceeds the supratherapeutic boundary. This system property is proven in Rocq using the Vehicle interactive theorem prover back-end to integrate the different proof systems. The end result is a verification pipeline that allows for a wide variety of treatment approaches whilst maintaining safety for each specific patient.

cs.LO

A New Rapid Test to End COVID

Despite 93.1% to 95.8% of the UK adult population having been vaccinated and currently 83.5% to 89.8% of adults having received at least two doses (1), and despite many households testing twice a week with lateral flow tests (2), R at the time of writing is 0.9 to 1.1, with a growth rate range for England of between -1% and +1% (3). Furthermore, up to 30% of infected individuals are going on to experience Long Covid (4). The crisis is far from over and as new variants of concern like Omicron spread, the situation is not under control, even in the highly vaccinated and tested UK and far less so in many countries. The problem is likely to be replicated in other countries with currently low infection levels as isolation is eased in future, even if these countries reach a high level of vaccination. Additionally, concerns have been raised about fall in immunity by 6 months after receiving the Pfizer and AstraZeneca vaccines (5), and the ability of Omicron to re-infect and cause illness in vaccinated people, with urgent booster jabs now being given to attempt to mitigate this. A solution to stop the spread of all variants of COVID-19 is needed now, and we present it here: CLDC, a rapid test that is 98%+ sensitive, low cost and scalable.

q-bio.OT